2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Haishan Jang

Session 6 – Sharing Biotech Successes
Date: 23 July (Thursday) 10:40 – 12:10 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Haishan Jang

CEO
BRIM Biotechnology, Inc.  




Haishan has over 30 years of extensive experience in the pharmaceutical industry, including at Centocor, DuPont, and Sanofi. She directed the scientific system, process and project management in biologic Clinical Pharmacology at Centocor, with responsibilities ranging across process integration/optimization for non-clinical, clinical pharmacology, pharmacokinetics, immune response, and clinical research activities.  Haishan has made contributions to the development of a few brand-name drugs such as Uroxatral®, Tirazon®, Remicade®, Simponi® and Stelara®. Prior to the formation of BRIM Biotechnology, Inc., Haishan held positions of President at TWI Biotechnology and COO of the Supra Incubation and Integration Center (Si2C), a Taiwan government sponsored incubation center.


Sharing the Experience of Biotech Success
2020 Taiwan BIO Awards Recipients:

- Emerging Company of the Year
  BRIM BIOTECHNOLOGY, INC.

• BRIM is a virtually operating company established in 2013 in Taipei, Taiwan, focusing on developing new drugs in various areas, including oncology and infectious disease. BRIM’s pipeline is generated from sourcing deals both within and outside of Taiwan, with its experienced team surveying many small molecules, peptides, biologics, and platform technologies at the lead optimization stage.  Projects are brought into BRIM through co-development partnerships or in-licensing deals, and development of the projects is conducted at global CROs and CMOs that fit the needs of the project.  Once clinical proof of concept (POC) is reached, the projects are partnered out for further clinical development.
 
• The Pigment Epithelial-Derived Factor (PEDF)-Derived Short Peptide (PDSP) platform with multiple mechanism of actions had been applied on many diseases including dry eye syndrome, osteoarthritis and corneal repair. The BRM421 for dry eye syndrome treatment demonstrated outstanding safety profile in the Phase 2 clinical trial and the Phase 2/3 clinical trial in now in progress in US. It is worth to mention that development and commercialization rights of BRM421 had been licensed out to China Grandpharma in 2020.